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1 Drug descriptio 
Generic/Brand name/ATC code:  
Trastuzumab emtansine/KadcylaTM/not yet assigned 
Developer/Company:  
Genentech, Inc., Roche Group 
Description:  
T-DM1 (trastuzumab emtansine) consists of two components: trastuzumab, 
a human epidermal growth factor receptor 2 (HER2) targeted monoclonal an-
tibody, conjugated to DM1, an anti-microtubule maytansinoid derivative [1]. 
The cellular cytotoxicity of trastuzumab is improved by the cytotoxicity of 
DM1. Trastuzumab binds to the surface of tumour cells, resulting in inter-
nalisation of DM1 and by distorting microtubule assembly in inhibition of 
cell division and proliferation of cancer cells that overexpress HER2 [1, 2]. 
Prior to initiation of T-DM1 therapy, HER2 positivity has to be confirmed. 
The drug is administered intravenously at a dosage of 3.6 mg/kg every 3 weeks 
(21-day cycle) until disease progression or unacceptable toxicity. Since throm-
bocytopenia is a common side-effect of T-DM1 therapy, platelet counts should 
be monitored before each cycle [3].  
 
 
2 Indication 
Trastuzumab emtansine (KadcylaTM) is indicated for previously treated pa-
tients with HER2-positive advanced/metastatic breast cancer (BC).  
 
 
3 Current regulatory status 
In Europe, T-DM1 is not yet licensed, but the Marketing Authorisation Ap-
plication has been accepted for review by the EMA in November 2012 [4]. 
In the U.S., T-DM1 was licensed in February 2013. It is indicated as a single 
agent, for the treatment of patients with HER2-positive, metastatic BC who 
previously received trastuzumab and a taxane, separately or in combination [3]. 
Patients should have either: 
 Received prior therapy for metastatic disease, or 
 Developed disease recurrence during or within six months  
of completing adjuvant therapy. 
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4 Burden of disease 
In 2010, about 5,000 women were newly diagnosed with and 1,500 died of BC 
in Austria [5] making BC the most common type of cancer in females. More 
than 80% of all cases occur in women aged over 50 years [6]. Risk factors as-
sociated with the development of BC are age, nulliparity, early menarche, 
genetic factors (e.g. genetic mutations such as of the BRCA1, BRCA2) or 
family history [7, 8]. Prognostic factors are age, menopausal status, tumour 
stage, histology and hormone receptor status [7].  
Important factors to determine the best management strategy are oestrogen-
receptor (ER) and progesterone-receptor (PR) status in the tumour tissue, 
HER2 status, menopausal status, and the general health of the patient [8]. In 
addition, the Tumor Node Metastasis (TNM) is also relevant for choosing the 
treatment strategy. This staging system reflects the extent of disease, which is 
used to inform treatment management decisions and to determine prognosis. 
Besides the primary tumour, the extent to which the regional lymph nodes 
are involved and the absence or presence of distant metastases are taken into 
account, leading to four main stage groupings (stage I to IV) [7]. Metastatic 
disease corresponds to stage IV. Metastases are most common in the bones, 
liver or the lungs [7].  
Metastatic disease at diagnosis is present in less than 10% of women [7] and 
evidence suggests that 20% to 25% of all women diagnosed with BC have tu-
mours over-expressing HER2 [9-11]. HER2 positivity is determined either by 
immunohistochemistry (IHC) or by fluorescent in situ hybridization (FISH) 
[12]. Due to various methods for determining HER2 status it might be the 
case though that these numbers are slightly overestimated and that rather 15–
20% overexpress HER2 [13]. However, applying these estimates to an Aus-
trian context would result in about 100 women with HER2 positive advanced 
metastatic BC. Median survival of women with metastatic BC is about 18 to 
24 months [8] and only 5–10% of women survive five or more years [7].  
BC with amplification and over-expression of HER2 are usually more aggres-
sive [7, 11] corresponding to a reduced overall survival (OS) and a shortened 
time to relapse [10] and HER2 status is also used to predict response to drugs 
such as trastuzumab or lapatinib or T-DM1 [7]. Additionally, primary re-
sistance to endocrine therapy might be associated with HER2 over-expres-
sion due to a cross-talk between ErbB1/ErbB2 and ER pathways and a link 
between responsiveness to chemotherapy and HER2 over-expression might 
exist [7]. 
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5 Current treatment 
Choice of therapy for BC is based on numerous factors like tumour histolo-
gy, axillary node status, hormone and HER2 receptor status, presence of me-
tastases as well as patient characteristics including menopausal status, age 
and co-morbidities [9, 14].  
Therapy of HER2 positive metastatic BC usually aims at symptom palliation, 
improvement of quality-of-life and extension of life [8]. Even though surgery 
and radiation therapy are indicated for symptom palliation in selected pa-
tients, the mainstay of therapy is systemic treatment. The backbone for the 
treatment of HER2 positive metastatic BC are HER2 targeted therapies (tra-
stuzumab: preferably in combination with single-agent chemotherapy or en-
docrine therapy but also as single-agent; lapatinib in combination with chemo-
therapy (i.e. capecitabine) or in combination with endocrine therapy for HR 
positive tumours [2, 7, 8]; pertuzumab).  
For patients progressing on HER2 targeted therapy, evidence has occurred 
in the last years that continuation of HER2 blockade still provides clinical 
benefit to patients [15-18]. Thus, treatment options include  
 trastuzumab + chemotherapy  
 lapatinib + trastuzumab (this combination is currently  
not licensed in Europe) or capecitabine 
 pertuzumab + trastuzumab 
 T-DM1 [15-18].  
 
 
6 Evidence 
A literature search was conducted on the 20th of February 2013 in 4 data-
bases (Medline, Embase, CRD, Cochrane Central). Search terms were “breast 
cancer”, “human epidermal growth factor receptor 2”, “trastuzumab emtan-
sine”, and “t dm1”. Overall 142 references were identified. Considered for 
inclusion were phase III studies (full text and abstracts) and phase II studies 
published as full text. If available, other study designs such as results from 
compassionate-use-programmes or meta-analysis were eligible. Overall, one 
phase III trial [19] and two phase II trials [20, 21] were included in this re-
port. 
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6.1 Efficacy and safety – Phase III studies 
Table 1: Summary of efficacy 
Study title  
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer [19, 22] 
Study  
identifier 
NCT00829166, EMILIA trial 
Design Randomized, open-label, international, multi-centre (213 centres in 26 countries),  
phase III; 1:1 randomisation, stratification according to world region, number of prior 
chemotherapies for unresectable, locally advanced or metastatic disease; disease 
involvement 
Duration  Enrolment: February 2009 – October 2011 
Median follow-up: 13 months (19 months for second interim 
analysis of OS) 
Cut-off dates for analyses: January 14, 2012 (for all endpoints 
except second interim analysis for overall survival);  
July 31, 2012: for second interim analysis of OS 
Hypothesis Superiority 
90% power to detect a hazard ratio of 0.75 for progression or death from any cause 
with T-DM1 as compared with lapatinib plus capecitabine and 80% power to detect a 
hazard ratio of 0.80 for death from any cause, with a two-sided alpha level of 0.05 
Funding Hoffmann – La Roche/Genentech 
Treatment 
groups 
(n=991) 
I(ntervention) 
(n=495) 
3.6 mg/kg of body weight T-DM1 i.v. every 21 days 
C(ontrol) 
(n=496) 
1250 mg/d lapatinib orally + 1000 mg/m² BSA capecitabine of 
every 12 hours (maximum planned daily dose, 2000 mg/m²) on 
days 1 through 14 of each 21-day treatment cycle 
Endpoints 
and 
definitions 
Progression-free 
survival assessed 
by independent 
review (primary 
outcome) 
PFS Time from randomization to progression (according to 
modified Response Evaluation Criteria in Solid Tumours 
(RECIST), version 1.0); or death from any cause 
Overall survival OS Time from randomization to death from any cause 
Progression-free 
survival 
(investigator-
assessed) 
PFS Time from randomization to first documented 
investigator-assessed disease progression or death from 
any cause, whichever occurs earlier [22] 
Objective 
response rate 
ORR Determined according to modified RECIST on the basis  
of an independent review of patients with measurable 
disease at baseline; responses were confirmed at least 28 
days after the initial documentation of a response [22] 
Duration of 
response 
DOR The period of time from the date of initial confirmed 
partial response (PR) or complete response (CR) until the 
date of progressive disease or death from any cause 
(whichever occurs earlier) [22] 
Time to 
symptom 
progression 
TSP Time from randomization to the first decrease of 5 points 
or more from baseline scores on the Trial Outcome Index 
of the patient-reported Functional Assessment of Cancer 
Therapy–Breast (FACT-B TOI, on which scores range from 
0 to 92, with higher scores indicating a better quality of 
life) in women with a baseline score and at least one 
postbaseline score 
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Results and analysis 
Analysis  
description 
ITT; two sided log-rank tests with stratification according to factors used for 
randomisation. 
Analysis  
population 
Inclusion  Documented progression of unresectable, locally advanced or 
metastatic centrally confirmed HER2-positive BC previously 
treated with a taxane and trastuzumab  
 HER2 positive status centrally confirmed and assessed by means 
of immunohistochemical analysis (with 3+ indicating positive 
status), fluorescence in situ hybridization (with an amplification 
ratio ≥2.0 indicating positive status), or both 
 Left ventricular ejection fraction of 50% or more determined by 
echocardiography or multiple-gated acquisition [MUGA] scanning 
 Eastern Cooperative Oncology Group PS ≤1  
Exclusion  Prior treatment with T-DM1, lapatinib, or capecitabine 
 Peripheral neuropathy of grade 3 or higher  
 Symptomatic central nervous system (CNS) metastases or treat-
ment for these metastases within 2 months before randomization 
 History of symptomatic congestive heart failure or serious 
cardiac arrhythmia requiring treatment; and a history of 
myocardial infarction or unstable angina within 6 months before 
randomization 
Characteristics Age (years (range)): I 53 (25–84) vs C 53 (24–83) 
ECOG 0/1 (%): I 60/39 vs C 63/35 
Site of disease involvement – visceral/non-visceral (%):  
I 67/33 vs C 68/32 
Hormone- receptor status – ER, PR+/ER,PR-/unknown (%): 
I 57/41/2 vs C 53/45/2 
Prior systemic therapy – anthracycline/other chemotherapy/biologic 
agent other than trastuzumab or pertuzumab/endocrine (%): 
I 61/78/3/41 vs C 61/77/4/41 
Prior chemotherapy regimens for locally advanced or metastatic 
disease – 0 or 1/>1 (%): I 61/39 vs C 61/39 
Prior trastuzumab treatment – metastatic or early BC or both/early 
BC only (%): I 84/16 vs C 84/16 
Descriptive 
statistics 
and 
estimated 
variability 
Treatment group Intervention  
(T-DM1) 
Control  
(lapatinib + capecitabine) 
Number of subjects N = 495 N = 496 
Median PFS (independent 
analysis), months 
9.6 6.4 
Median PFS (investigator 
assessed), months 
9.4 5.8 
Median OS (2nd interim 
analysis), months 
30.9 
 
25.1 
 
Survival rates, % (95% CI) 
1-year  
2- year  
 
85.2 (82.0–88.5) 
64.7 (59.3–70.2) 
 
78.4 (74.6–82.3) 
51.8 (45.9–57.7) 
ORR, % (95% CI) 
CR, % 
PR, % 
43.6 (38.6–48.6) 
1.0 
42.6 
30.8 (26.3–35.7)* 
0.5 
30.3 
Median DOR, months 
(95% CI) 
12.6 (8.4–20.8) 6.5 (5.5–7.2) 
Median TSP, months 7.1 4.6 
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Effect 
estimate per 
comparison 
Comparison groups  I vs C 
PFS  
(independent analysis) 
HR 0.65 
95% CI 0.55–0.77 
P value  <0.001 
PFS  
(investigator assessed) 
HR  0.66 
95% CI 0.56–0.77 
P value <0.001 
OS  
(1st interim analysis)  
HR 0.62 
95% CI 0.48–0.81 
P value  0.0005 
OS  
(2nd interim analysis) 
HR 0.68 
95% CI 0.55–0.85 
P value  <0.001 
TSP HR  0.80 
95% CI 0.67–0.95 
P value  0.012 
* P<0.001  
Abbreviations: BC = breast cancer; BSA = body-surface area; C = control, CI = confidence interval, CR = complete response, 
DOR = duration of response, ECOG = Eastern Cooperative Oncology Group, HR = hazard ratio, I = intervention, i.v. = intra-
venously; kg = kilogram, ORR = objective response rate, OS = overall survival, PFS = progression- free survival, PR = partial 
response, TSP = time to symptom progression 
 
Table 2: Adverse Events 
Outcome n (%) I (N= 490) C (N=488) 
Grade (according to CTC version 3.0) Any Grade Grade 3 or  
4 events 
Any Grade Grade 3 or 4 
Any event 470 (95.9) 200 (40.8) 477 (97.7) 278 (57.0) 
Diarrhoea  114 (23.3) 8 (1.6) 389 (79.7) 101 (20.7) 
Palmar-plantar erythrodysesthesia 6 (1.2) 0 283 (58.0) 80 (16.4) 
Vomiting 93 (19.0) 4 (0.8) 143 (29.3) 22 (4.5) 
Neutropenia 29 (5.9) 10 (2.0) 42 (8.6) 21 (4.3) 
Hypokalemia 42 (8.6) 11 (2.2) 42 (8.6) 20 (4.1) 
Fatigue 172 (35.1) 12 (2.4) 136 (27.9) 17 (3.5) 
Nausea 192 (39.2) 4 (0.8) 218 (44.7) 12 (2.5) 
Mucosal inflammation 33 (6.7) 1 (0.2) 93 (19.1) 11 (2.3) 
Anaemia 51 (10.4) 13 (2.7) 39 (8.0) 8 (1.6) 
Elevated ALT 83 (16.9) 14 (2.9) 43 (8.8) 7 (1.4) 
Elevated AST 110 (22.4) 21 (4.3) 46 (9.4) 4 (0.8) 
Thrombocytopenia 137 (28.0) 63 (12.9) 12 (2.5) 1 (0.2) 
Bleeding NR (29.8) NR (1,4) NR (15.8) NR (0,8) 
Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, NR = not reported 
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The EMILIA trial, a phase III study, compared T-DM1 to lapatinib + cape-
citabine in overall 991 patients with HER positive advanced BC. All patients 
had been treated previously with trastuzumab and a taxane for their ad-
vanced/ metastatic disease. HER2 status was determined by FISH or IHC. 
496 patients were randomised to lapatinib (1250 mg/d orally) + capecitabine 
(1000 mg/m² body surface area capecitabine orally every 12 hours on days 
1–14 of each 21 day cycle) and 495 to T-DM1 (3.6 mg/kg every 21 days).  
Median age of the study population was 53 years; the majority of women had 
ECOG status 0 and visceral involvement. In both groups, slightly more pa-
tients were hormone-receptor status positive (>53%) than negative (<45%). 
61% in both groups were either treatment-naïve or had received a maximum 
of 1 chemotherapy for their metastatic disease, whereas the rest had received 
more than 1 regimen. Most patients (i.e. 84% in both groups) had been treated 
with prior trastuzumab for metastatic, for early BC or for both and 16% in 
each group had received trastuzumab for early disease only.  
Dose-reductions were necessary in 27.3% of patients treated with lapatinib, 
in 53.4% treated with capecitabine and in 16.3% of the T-DM1 group respec-
tively. Treatment discontinuation due to AEs were most frequently observed 
with capecitabine in the safety population (capecitabine: 9.4%, lapatinib: 
7.6%, T-DM1: 5.9%).  
PFS as assessed by independent review, the primary outcome, was 9.6 months 
in the T-DM1 group in comparison to 6.4 months in the lapatinib group, 
yielding a HR of 0.65 (95%CI 0.55–0.77; p<0.001) after a median follow-up 
of 13 months. These findings were consistent across clinical relevant sub-
groups, with the exception of patients aged ≥75 years. After a median of 19 
months follow-up, OS was 30.9 months in the T-DM1 group and 25.1 months 
in the lapatinib + capecitabine group (HR = 0.68; 95%CI 0.55–0.85; p<0.001). 
More favourable results for the T-DM1 group were also found for ORR (43.6% 
vs 30.8%, p<0.001) and DOR (12.6 months vs 6.5 months) and median time 
to symptom progression was also longer (7.1 months vs 4.6 months; HR = 0.80; 
95%CI 0.67–0.95; p<0.012).  
Different profiles in adverse events (AEs) were seen for the two groups. Any 
AE of any grade occurred in nearly all patients in both groups. Any event of 
grade 3 or 4 was less frequent in patients treated with T-DM1 (40.8% vs 
57.0%). The most common grade 3 or 4 AE in the T-DM1 group was throm-
bocytopenia, followed by elevated liver enzymes and anaemia, whereas pa-
tients treated with lapatinib + capecitabine experienced more often diar-
rhoea, palmar-plantar erythrodysaesthesia or vomiting. Overall 5 deaths due 
to AEs were seen in both treatment groups; 4 in the lapatinib + capecitabine 
group (coronary artery disease, multi-organ failure, coma and hydrocephalus) 
and 1 (metabolic encephalopathy after CNS progression) in the T-DM1 group. 
Reported cardiac side-effects, side-effects associated with trastuzumab ther-
apy, were a decline in left ventricular ejection fraction to less than 40% from 
baseline in 3 patients in each group.  
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6.2 Efficacy and safety – further studies 
A single-arm phase II study [21] encompassing 112 patients evaluated effi-
cacy and safety of T-DM1 (3.6 mg/kg every 3 weeks) in heavily pre-treated 
women (median number of prior anticancer agents in all disease setting was 8) 
for a minimum of 12 months. For inclusion, HER2 positivity had initially 
been determined by local laboratories and was retrospectively confirmed by 
a central laboratory in 78%. The primary outcome ORR determined by an 
independent review facility was 25.9% only due to partial responses. Median 
DOR was not reached (95%CI 6.2 months – not estimable) and median PFS 
was 4.6 months (95%CI 3.9–8.6 months). More favourable results were found 
for these outcomes in patients with retrospectively confirmed HER2 positiv-
ity than in those with unconfirmed HER2 positive status. The most common 
AEs of all grades were fatigue (65.2%), nausea (50.9%) and headache (40.2%), 
but mainly of grade 1. Higher grade AEs (i.e. grade 3 or 4) were hypokalae-
mia (8.9%), thrombocytopenia (8.0%) and fatigue (4.5%).  
Krop et al. [20, 23] reported the results of a single-arm phase II study com-
prising 110 pre-treated and HER2 positive (assessed by local laboratory cri-
teria) metastatic BC patients. T-DM1 (3.6 mg/kg every 3 weeks) was admin-
istered to patients who had been treated with at least two prior HER2 target-
ed therapies. Enrolled patients had received a median of 7 prior agents in-
cluding trastuzumab, lapatinib, an anthracycline, a taxane and capecitabine 
for metastatic BC. Median follow-up was 17.4 months. ORR, the primary 
outcome, was assessed by an independent review facility, and was 34.5% 
(95%CI 26.1%–43.9%), all of these being partial responses. Median PFS was 
6.9 months (95%CI 4.2–8.4 months) and median DOR was 7.2 months 
(95%CI 4.6 – not estimable). HER2 status was reassessed by central testing, 
and confirmed HER2 positivity in 84.2% of patients. For these patients, bet-
ter results were obtained in ORR (HER2 positivity confirmed: 41.3% vs 
HER2 positivity not confirmed: 20.0%) and PFS (HER2 positivity confirmed: 
7.3 months vs HER2 positivity not confirmed: 2.8 months). The most fre-
quent AEs of any grade were fatigue (61.8%), thrombocytopenia (38.2%) and 
nausea (37.3%). Higher grade AEs were mainly of grade 3 with thrombocy-
topenia (7.3%) and fatigue (4.5%) being the most common ones. Side-effects 
of grade 4 were rare and included thrombocytopenia (1.8%), spinal cord com-
pression (1.8%), cellulitis (0.9%) and abdominal pain (0.9%).The only grade 
5 AE was pneumonia (0.9%).  
 
 
7 Estimated costs 
No cost estimates are available for Austria. In the U.S. monthly treatment 
costs of $ 9,800 (= € 7,660) are mentioned for T-DM1 only [24], totalling up 
to treatment costs of $ 94,000.  
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8 Ongoing research 
At http://clinicaltrials.gov/ and at https://www.clinicaltrialsregister.eu/ctr-
search/ 2 phase III studies for the investigated indication were found: 
 NCT01419197: (TH3RESA): randomized, multicentre, two-arm, open-
label study (TH3RESA) will evaluate T-DM1 in comparison with treat-
ment of the physician's choice in patients with metastatic or unresec-
table locally advanced/recurrent HER2-positive BC. Estimated study 
completion date: October 2015. 
 NCT01702571: multi-centre, single-arm study will assess the safety and 
the efficacy of T-DM1 in patients with HER2-positive locally advanced 
or MBC who have received prior anti-HER2 and chemotherapy-based 
treatment. Estimated study completion date: March 2017.  
Moreover, phase III trials were found investigating T-DM1 for BC, for exam-
ple, as first-line therapy in combination with pertuzumab (NCT01120184) or 
as adjuvant therapy in comparison to trastuzumab (NCT01772472). T-DM1 
is also being assessed for gastric cancer.  
 
 
9 Commentary 
T-DM1, currently not yet licensed in Europe but in the U.S., is a new drug 
combining the HER2 targeted agent trastuzumab with DM1 a cytotoxic may-
tansine derivative. This drug has been licensed in the U.S. for patients with 
HER2 positive metastatic BC who have previously received trastuzumab and 
a taxane.  
A phase III trial, the EMILIA trial, investigated this indication in overall 
991 patients. Independently assessed PFS, the primary outcome, was extend-
ed by 3.2 months in comparison to patients treated with lapatinib + capecit-
abine (HR = 0.65; 95%CI 0.55–0.77), a regimen commonly used for patients 
with disease progression on trastuzumab therapy. This result was consistent 
across clinically relevant subgroups, with the exception of patients aged ≥75 
years. For the whole study population, the difference in OS was 5.8 months 
(HR = 0.68; 95%CI 0.55–0.85; p<0.001). Also other outcomes such as ORR, 
DOR and time to symptom progression consistently favoured T-DM1. Side 
effects profiles differed between the two groups but were less frequent in pa-
tients receiving the trastuzumab conjugate than in those in the control group.  
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with other agents and 
for gastric cancer 
T-DM1 not licensed in 
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after trastuzumab and 
taxane therapy 
+3.2 months in PFS for 
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across subgroups but not 
for patients ≥75 years 
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favoured T-DM1 and 
fewer side-effects 
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Due to the fact that most patients treated with anti-HER2 therapy, mostly 
trastuzumab, have disease progression while on therapy, new treatment strat-
egies were needed. In recent years, evidence has emerged that continuation 
of HER2 blockade, despite disease progression under HER2 targeted thera-
py, may still yield clinical benefit [25, 26]. This has led to the development 
of new therapeutic options including T-DM1. Since treatment options com-
monly used within this setting consist of combination therapies (trastuzu-
mab + alternative chemotherapeutic regimen/other HER2 targeted therapy; 
lapatinib in combination with chemotherapy [27]), the rationale for develop-
ing an antibody-drug conjugate like T-DM1 was to increase the targeted de-
livery of chemotherapy while reducing toxicities associated with chemother-
apy [27, 28]. Furthermore, use of single agent T-DM1 reduces the need of 
concomitant systemic chemotherapy and thus increases the ease of admin-
istration.  
Even though the EMILIA trial comprised a rather heterogeneous study popu-
lation favourable results for most subgroups were achieved (e.g. ER status, 
prior systemic therapy for metastatic BC, prior trastuzumab therapy). How-
ever, since mechanisms of resistance, either de-novo or acquired, to HER2 
targeted therapies are diverse, HER2 status as the only criterion for selecting 
patients for costly therapies is increasingly challenged [27, 29]. A more re-
fined characterisation of pathways involved in resistance development and of 
molecular predictors for choosing new treatment options is needed and will 
allow more tailored treatment approaches [29, 30] which is important since 
besides T-DM1 other agents such as tanespimycin or neratinib are under 
evaluation [30]. 
One of the subgroups for which no improved outcomes were found was for 
patients aged ≥75 years, but since this group comprised only 25 patients, no 
definite conclusions can be drawn. Thus efficacy of T-DM1 for elderly pa-
tients, and due to the fact that enrolled patients had a good performance sta-
tus (i.e. 0 or 1) also for co-morbid patients, needs to be investigated further.  
In addition, despite the fact that cardiac side-effects did not occur more fre-
quently in the T-DM1 group than in the control arm, the FDA recommend-
ed placing cardiac toxicity in a boxed warning on the label, because cardio-
toxicity is an AE known to be linked to HER2 targeted therapies [31, 32]. For 
this outcome, as well as all others, long-term data on T-DM1 therapy would 
be helpful, foremost since optimal duration of HER2 targeted therapies are 
unknown. This fact is of further importance, because T-DM1 is also under in-
vestigation in the adjuvant and neoadjuvant setting (NCT01196052) and also 
for previously untreated patients with metastatic BC (NCT01120184) [30].  
Furthermore, besides T-DM1 single-agent therapy, combinations with, for 
example, pertuzumab are being tested [30]. Even though cost estimates for 
Austria are not available yet, combination therapies with several expensive 
therapies for a long period of time will result in high treatment costs [33]. 
With respect to costs but also in terms of clinical outcomes, it can be ques-
tioned whether lapatinib + capecitabine was the most appropriate compara-
tor. Since trastuzumab either in combination with lapatinib (currently not 
licensed in this combination in Europe) or with capecitabine are treatment 
options recommended by several guidelines [16, 18], the comparison to a 
trastuzumab containing therapy would have been of utmost interest, foremost, 
because both agents are manufactured by the same company. and the patent 
for trastuzumab will expire in July 2014 [34]. 
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